Lantheus (LNTH) Stock May Be 14% Undervalued After FDA Approval

Lantheus Holdings has had a powerful run in recent years, and the question now is whether the current share price lines up with the cash flows the business can realistically generate. With the stock near US$99.74, investors are increasingly focused on what its stream of future cash actually supports.

• Over the past 5 years, Lantheus Holdings has returned about 303.0%, which puts real pressure on the valuation argument to be grounded in the strength and durability of its cash flows.
• Recent FDA approval for BRAVNETSA and progress on the SPARROW prostate cancer imaging trial can reshape expectations for future revenue timing and capital needs, which feeds directly into any cash flow based valuation work.
• If you'd rather focus on earnings, this one's for you. See what Lantheus Holdings's 23.6x P/E says about the price.

For investors, the debate is whether Lantheus Holdings' current market price is properly supported by the cash flows implied in a Discounted Cash Flow (DCF) view of the business.

To stress test whether Lantheus Holdings' recent 303.0% five year return is fairly supported by its cash flows, you can apply the same cash flow lens to a broader set of 32 high quality undervalued stocks

Is Lantheus Holdings Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model here focuses on what Lantheus Holdings can return to shareholders through future free cash generation. Latest twelve month free cash flow sits at about $343.6 million, with the model assuming modest growth from there rather than aggressive expansion or a sharp drop off.

On that cash flow path, the DCF output suggests an intrinsic value that is modestly above the current share price of $99.74. The projections imply Lantheus Holdings settling into a steady, slightly rising free cash flow profile over the coming decade, which matches a business investing in trials and approvals but not betting everything on hyper growth. Because the recent FDA approval for BRAVNETSA points to ongoing capital needs as well as potential new inflows, the market may be giving some discount to those future cash streams. Find out what Lantheus Holdings could be worth using our Discounted Cash Flow (DCF) estimate.

The Lantheus Holdings Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Lantheus Holdings pick up where the DCF question leaves off and spell out which paths for growth, profitability and earnings would need to play out for the shares to look materially higher or lower than today. Each scenario anchors its number to a clear view on how Lantheus Holdings' revenue mix, cost structure and risk profile might evolve next, giving you something concrete to revisit as new information arrives on the Community page.

One of the top community narratives on Lantheus Holdings: 7% undervalued

"Recent acquisitions (Evergreen and Life Molecular Imaging) enhance Lantheus's manufacturing capabilities, broaden its product portfolio, and provide an immediate and scalable entry into high growth…"

Discover why this Narrative puts Lantheus Holdings at 7% undervalued.

Lantheus Holdings’ valuation is only half the story

Before making any decision on Lantheus Holdings, it is worth asking who is steering the business, how their rewards line up with your interests, and what that track record really looks like. See who runs Lantheus Holdings and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com